RECENT POSTS
Beovu: What’s the latest with the ophthalmic community’s concerns?
Post by Admin, July 1, 2020.Reports and opinions keep pouring in about Novartis’ Beovu® (brolucizumab), meant to treat wet or neovascular age-related macular degeneration (nAMD). In February, the American Society of Retina Sp...
Read More